Gut microbiota may underlie the predisposition of healthy individuals to COVID-19

Wanglong Gou^{1,4#}, Yuanqing Fu^{1,4#}, Liang Yue^{3,4#}, Geng-dong Chen^{2#}, Xue Cai^{3,4#}, Menglei Shuai^{1,4#}, Fengzhe Xu^{1,4#}, Xiao Yi^{3,4}, Hao Chen^{3,4}, Yi Zhu^{3,4}, Mian-li Xiao², Zengliang Jiang¹, Zelei Miao¹, Congmei Xiao¹, Bo Shen⁵, Xiaomai Wu⁵, Haihong Zhao⁵, Wenhua Ling², Jun Wang⁶, Yu-ming Chen^{2*}, Tiannan Guo^{3,4*}, Ju-Sheng Zheng^{1,4,7*}

¹Key Laboratory of Growth Regulation and Translation Research of Zhejiang
 Province, School of Life Sciences, Westlake University, Hangzhou 310024, China;
 ²Guangdong Provincial Key Laboratory of Food, Nutrition and Health; Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China;

³Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China;

⁴Institute of Basic Medical Sciences, Westlake Institute for Advanced Study,

Hangzhou 310024, China;

⁵Taizhou Hospital, Wenzhou Medical University, 150 Ximen Street, Linhai 317000, Zhejiang Province, China;

⁶ CAS Key Laboratory for Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China.

⁷Lead Contact

#These authors contributed equally

*Correspondence: chenyum@mail.sysu.edu.cn (Y.M.C.);

guotiannan@westlake.edu.cn (T.G.); zhengjusheng@westlake.edu.cn (J.S.Z.)

1 SUMMARY

2 The COVID-19 pandemic is spreading globally with high disparity in the susceptibility of the disease severity. Identification of the key underlying factors for 3 this disparity is highly warranted. Here we describe constructing a proteomic risk 4 score based on 20 blood proteomic biomarkers which predict the progression to 5 severe COVID-19. We demonstrate that in our own cohort of 990 individuals without 6 infection, this proteomic risk score is positively associated with proinflammatory 7 8 cytokines mainly among older, but not younger, individuals. We further discovered that a core set of gut microbiota could accurately predict the above proteomic 9 biomarkers among 301 individuals using a machine learning model, and that these gut 10 microbiota features are highly correlated with proinflammatory cytokines in another 11 12 set of 366 individuals. Fecal metabolomic analysis suggested potential amino acid-related pathways linking gut microbiota to inflammation. This study suggests 13 that gut microbiota may underlie the predisposition of normal individuals to severe 14 COVID-19. 15

17 Introduction

With the coronavirus disease 2019 (COVID-19) defined as 'global pandemic' and 18 19 spreading worldwide at an unprecedented speed, more than two million individuals have been infected globally since its first detection in December 2019 to mid-April 20 2020 (WHO, 2020). So far, many research papers have been published to characterize 21 the clinical features of the COVID-19 patients, revealing that those individuals who 22 are older, male or having other clinical comorbidities are more likely to develop into 23 severe COVID-19 cases (Chen et al., 2020; Huang et al., 2020). Yet, little is known 24 25 about the potential biological mechanisms or predictors for the susceptibility of the disease. 26

27

It is known that COVID-19 is caused by severe acute respiratory syndrome 28 coronavirus 2 (SARS-CoV-2), which enters human cells by binding to angiotensin 29 converting enzyme 2 (ACE2) as its receptor (Yan et al., 2020). Of note, ACE2 is an 30 important regulator of intestinal inflammation, and that the expression of ACE2 is 31 32 higher in the ileum and colon than in lung (Hashimoto et al., 2012; Zhang et al., 2020). ACE2 also has a major impact on the composition of gut microbiota, thus affecting 33 cardiopulmonary diseases (Cole-Jeffrey et al., 2015). Moreover, over 60% of patients 34 with COVID-19 report evidence of gastrointestinal symptoms, such as diarrhoea, 35 nausea and vomiting, and that patients with gastrointestinal symptoms had overall 36 more severe/critical diseases (Jin et al., 2020; Lin et al., 2020; Ng and Tilg, 2020). 37 Taken together, the available evidence suggests a potential role of gut microbiota in 38 the susceptibility of COVID-19 progression and severity. 39

40

Based on a recent investigation into the blood biomarkers of COVID-19 patients, we identified a set of proteomic biomarkers which could help predict the progression to severe COVID-19 among infected patients (Shen et al., 2020). The newly discovered proteomic biomarkers may help early prediction of severe COVID-19. However, the question remains as to whether this set of proteomic biomarkers could be used in healthy (non-infected) individuals to help explain the disease susceptibility. It is also

4

47 unclear whether gut microbiota could regulate these blood proteomic biomarkers48 among healthy individuals.

49

To address the above unresolved questions, we integrated blood proteomics data from 50 31 COVID-19 patients and multi-omics data from a Chinese population without 51 52 infection living in Guangzhou, involving 2413 participants (Figure 1; Figure S1; Table S1). Based on the COVID-19 patient data, we constructed a blood proteomic 53 risk score (PRS) for the prediction of COVID-19 progression to clinically severe 54 phase. Then, among 990 healthy individuals with the data of proteome and blood 55 inflammatory biomarkers, we investigated the association of the COVID-19-related 56 PRS with inflammatory biomarkers as a verification of the PRS with disease 57 susceptibility in normal non-infected individuals. Next, we identified core gut 58 microbiota features which predicted the blood proteomic biomarkers of COVID-19 59 using a machine-learning model. We conducted further fecal metabolomics analysis to 60 reveal potential biological mechanisms linking gut microbiota to the COVID-19 61 62 susceptibility among non-infected individuals. Finally, we demonstrated the contribution of 40 host and environmental factors to the variance of the above 63 identified core gut microbiota features. 64 65 Results 66 Predictive proteomic profile for severe COVID-19 is correlated with 67 inflammatory factors among healthy individuals 68

Based on a prior serum proteomic profiling of COVID-19 patients, 22 proteomic

70 biomarkers contributed to the prediction of progression to severe COVID-19 status

- 71 (Shen et al., 2020). Using this cohort, we constructed a blood PRS among the 31
- 72 COVID-19 patients (18 non-severe cases and 13 severe cases) based on 20 proteomic
- biomarkers (Table S2). We only used 20 of the 22 proteins for our PRS construction
- ⁷⁴ because 2 proteins were unavailable in our large proteomics database among
- 75 non-infected participants for the further analysis. Among the COVID-19 patients,
- 76 Poisson regression analysis indicated that per 10% increment in the PRS there was

5

77	associated a 57% higher risk of progressing to clinically severe phase (RR, 1.57; 95%
78	CI, 1.35-1.82; Figure 2A), in support of the PRS as being a valid proxy for the
79	predictive biomarkers of severe COVID-19.

80

To explore the potential implication of the PRS among non-COVID-19 individuals, 81 we constructed the PRS using the same set of 20 blood proteins among a cohort of 82 non-infected participants with data of both proteomics and inflammatory markers 83 (n=990). The blood proteomic data was based on the baseline serum samples of the 84 cohort (Figure S1). We investigated the correlation between the PRS and blood 85 inflammatory markers IL-1 β , IL-6, TNF- α and hsCRP. The PRS had a significantly 86 positive correlation with serum concentrations of hsCRP and TNF- α (p<0.001 and 87 p<0.05, respectively), but not other markers (Figure 2B). As age and sex are very 88 important factors related to the susceptibility to SARS-CoV-2 infection, we 89 performed subgroup analysis stratified by age (<58 years vs. ≥ 58 years, with 58 years 90 as the median age of this cohort) and sex. Interestingly, we found that higher PRS was 91 92 significantly correlated with higher serum concentrations of all the aforementioned inflammatory markers among older individuals (>58 years, n=493), but not among 93 younger individuals (≤58 years, n=497) (Figure 2B and 2C). The PRS did not show 94 any differential association with the inflammatory markers by sex (Figure S2). 95 Whether the identified proteomic changes causally induce immune activation or 96 consequences of the immune response are not clear at present, but the finding 97 supports the hypothesis that the PRS may act as a biomarker of unbalanced host 98 99 immune system, especially among older adults.

100

101 Core microbiota features predict COVID-19 proteomic risk score and host 102 inflammation

103 To investigate the potential role of gut microbiota in the susceptibility of healthy

104 individuals to COVID-19, we next explored the relationship between the gut

105 microbiota and the above COVID-19-related PRS in a sub-cohort of 301 participants

106 with measurement of both gut microbiota (16s rRNA) and blood proteomics data

(Figure S1). Gut microbiota data were collected and measured during a follow-up

6

visit of the cohort participants, with a cross-sectional subset of the individuals (n=132) 108 having blood proteomic data at the same time point as the stool collection and another 109 independent prospective subset of the individuals (n=169) having proteomic data at a 110 next follow-up visit \sim 3 years later than the stool collection. 111 112 Among the cross-sectional subset, using a machine learning-based method: 113 LightGBM and a very conservative and strict tenfold cross-validation strategy, we 114 identified 20 top predictive operational taxonomic units (OTUs), and this subset of 115 core OTUs explained an average 21.5% of the PRS variation (mean out-of-sample 116 $R^2=0.215$ across ten cross-validations). The list of these core OTUs along with their 117 taxonomic classification is provided in Table S3. These OTUs were mainly assigned 118 to Bacteroides genus, Streptococcus genus, Lactobacillus genus, Ruminococcaceae 119 family, Lachnospiraceae family and Clostridiales order. 120 121 122 To test the verification of the core OTUs, the Pearson correlation analysis showed the coefficient between the core OTUs-predicted PRS and actual PRS reached 0.59 123 (p<0.001), substantially outperforming the predictive capacity of other demographic 124 characteristics and laboratory tests including age, BMI, sex, blood pressure and blood 125 lipids (Pearson's r =0.154, p=0.087) (Figure 3A). Additionally, we used co-inertia 126 analysis (CIA) to further test co-variance between the 20 identified core OTUs and 20 127 predictive proteomic biomarkers of severe COVID-19, outputting a RV coefficient 128 (ranged from 0 to 1) to quantify the closeness. The results indicated a close 129 130 association of these OTUs with the proteomic biomarkers (RV=0.12, p<0.05) (Figure

131 S3A). When replicating this analysis stratified by age, significant association was

132 observed only among older participants (age≥58, n=66; RV=0.22, p<0.05) (Figure

133 S3B and S3C).

134

107

135 Importantly, the above results from cross-sectional analyses were successfully

136 replicated in the independent prospective subset of 169 individuals, which showed a

137	Pearson's r of 0.18 between the core OTUs-predicted PRS versus actual PRS (p<0.05),
138	also outperforming the predictive capacity of the above demographic characteristics
139	and laboratory tests (Pearson's r =0.08, p=0.31) (Figure 3A). These findings support
140	that change in the gut microbiota may precede the change in the blood proteomic
141	biomarkers, inferring a potential causal relationship.
142	
143	To further verify the reliability of these core OTUs, in another larger independent
144	sub-cohort of 366 participants (Figure S1), we examined the cross-sectional
145	relationship between the core OTUs and 10 host inflammatory cytokines including
146	IL-1 β , IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, TNF- α and IFN- γ , and found 11
147	microbial OTUs were significantly associated with the inflammatory cytokines
148	(Figure 3B). Specifically, Bacteroides genus, Streptococcus genus and Clostridiales
149	order were negatively correlated with most of the tested inflammatory cytokines,
150	whereas Ruminococcus genus, Blautia genus and Lactobacillus genus showed
151	positive associations.
152	
153	Fecal metabolome may be the key to link the PRS-related core microbial features
154	and host inflammation
155	We hypothesized that the influences of the core microbial features on the PRS and
156	host inflammation were driven by some specific microbial metabolites. So we
157	assessed the relationship between the core gut microbiota and fecal metabolome
158	among 987 participants, whose fecal metabolomics and 16s rRNA microbiome data
159	were collected and measured at the same time point during the follow-up visit of the
160	participants (Figure S1). After correction for the multiple testing (FDR<0.05), a total

- 161 of 183 fecal metabolites had significant correlations with at least one selected
- 162 microbial OTU. Notably, 45 fecal metabolites, mainly within the categories of amino
- acids, fatty acids and bile acids, showed significant associations with more than half
- 164 of the selected microbial OTUs (Figure 4A), these metabolites might play a key role
- 165 in mediating the effect of the core gut microbiota on host metabolism and
- 166 inflammation.

8

Based on these key metabolites, we performed metabolic pathway analysis to 167 elucidate possible biological mechanisms. The results showed that these 45 fecal 168 metabolites were mainly enriched in three pathways, namely aminoacyl-tRNA 169 biosynthesis pathway, arginine biosynthesis pathway, and valine, leucine and 170 isoleucine biosynthesis pathway (Figure 4B). There were 15 fecal metabolites 171 involved in the aminoacyl-tRNA biosynthesis pathway, which is responsible for 172 adding amino acid to nascent peptide chains and is a target for inhibiting cytokine 173 174 stimulated inflammation (Figure 4C). Additionally, 4 metabolites were associated with arginine biosynthesis pathway and 3 metabolites were enriched in valine, leucine 175 and isoleucine (known as branch-chain amino acids, BCAAs) biosynthesis pathway 176 (Figure 4C). 177

178

179 Host and environmental factors modulate the PRS-related core microbial OTUs

As demographic, socioeconomic, dietary and lifestyle factors may all be closely 180 related to the gut microbiota, we explored the variance contribution of these host and 181 182 environmental factors for the identified core OTU composition. A total of 40 items belonging to two categories (i.e., demographic/clinical factors and dietary/nutritional 183 factors) were tested (Figure 5), which together explained 3.6% of the variation in 184 interindividual distance of the core OTU composition (Bray-Curtis distance). In the 185 demographic/clinical factors which explained 2.4% of the variation, we observed 186 associations of 9 items (i.e., sex, education, physical activity, diastolic blood pressure, 187 blood glucose, blood lipids and medicine use for type 2 diabetes) with inter-individual 188 distances in the core OTU composition (PERMANOVA, p<0.05; Figure 5). While in 189 190 the dietary/nutritional category (1.1% variance was explained), only dairy consumption significantly contributed to the variance of the core OTU composition. 191

192

193 Discussion

Our findings suggest that, among healthy non-infected individuals, gut microbial
features are highly predictive of the blood proteomic biomarkers of severe COVID-19
disease. The disruption of the corresponding gut microbiome features may potentially

197	predispose healthy individuals to abnormal inflammatory status, which may further
198	account for the COVID-19 susceptibility and severity. The fecal metabolomics
199	analysis reveals that amino acid-related pathway may provide the key link between
200	the identified core gut microbiota, inflammation and COVID-19 susceptibility.
201	Furthermore, modifications on host and environmental factors are likely to influence
202	the above core gut microbiota compositions.
203	
204	Accumulating evidence suggests that "cytokine storm", an excessive production of
205	inflammatory cytokines, may be an important mechanism leading to the severity and
206	death of COVID-19 patients (Huang et al., 2020; Yang et al., 2020). Therefore,
207	anticytokine therapy for the suppression of the hyperinflammatory status of the
208	patients is a recommended strategy to treat severe COVID-19 patients (Mehta et al.,
209	2020; Monteleone et al., 2020). Among the 20 proteomic predictors of severe
210	COVID-19, several most upregulated proteins are activated acute phase proteins,
211	including serum amyloid A-1 (SAA1), SAA2, SAA4, alpha-1-antichymotrypsin
212	(SERPINA3), complement 6 (C6) and complement factor B (CFB) (Shen et al., 2020).
213	These proteins may be activated together with proinflammatory cytokines such as
214	IL-6 and TNF- α following the invasion of the SARS-CoV-2. Therefore, this set of
215	proteomic biomarkers may serve as an important biomarker or therapeutic target for
216	treating SARS-CoV-2 infection. Beyond the previous data from the COVID-19
217	patients, our current study based on data from healthy non-infected participants
218	consistently supports that the proteomic biomarkers (integrated into a score) are
219	positively associated with proinflammatory cytokines, especially among those with an
220	older age. These results imply that the proteomic changes my precede the progression
221	of COVID-19 to severe phase. Moreover, our finding of more significant associations
222	between PRS and proinflammatory cytokines among older people agree with the
223	observation during COVID-19 outbreak that older individuals are more susceptible to
224	the virus, leading to severity of the disease, due to the induced hyperinflammation or
225	"cytokine storm" (Chen et al., 2020; Zhou et al., 2020).

10

In the present study, the core gut microbial features (20 OTUs), with a satisfied 226 performance, outperform demographic characteristics and laboratory tests in 227 predicting the blood proteomic biomarkers, which highlights a potential role of gut 228 microbiota in regulating the susceptibility of COVID-19 among normal individuals. 229 In fact, maintaining gut homeostasis has been suggested as a treatment option in the 230 "Diagnosis and Treatment Plan of Corona Virus Disease 2019 (Tentative Sixth 231 Edition)" issued by National Health Commission of China, as to keep the equilibrium 232 233 for intestinal microecology and prevent secondary bacterial infection (National Health Commission (NHC) of the PRC, 2020). Growing evidence has shown that microbiota 234 plays a fundamental role on the induction, training and function of the host immune 235 system, and the composition of the gut microbiota and its activity are involved in 236 237 production of inflammatory cytokines (Belkaid and Hand, 2014; Cani and Jordan, 2018). Prior studies reported that Lactobacillus genus was positively associated with 238 IL-6 and IFN-y, while *Blautia* genus was positively associated with IL-10 (Jiang et al., 239 2012; Pohjavuori et al., 2004; Yoshida et al., 2001); these relationships were 240 241 replicated in our study. Besides, we found the PRS-related OTUs belonging to Bacteroides genus and Streptococcus genus were negatively associated with most 242 proinflammatory factors. These results further support the reliability of the selected 243 core OTUs. 244

245

246 Fecal metabolomics analyses for the identified core gut microbial OTUs suggest that

these OTUs may be closely associated with amino acid metabolism, especially

aminoacyl-tRNA biosynthesis pathway, arginine biosynthesis pathway, and valine,

249 leucine and isoleucine biosynthesis pathway. As metabolic stress pathways and

250 nutrient availability instruct immunity, amino acid levels in the tissue

251 microenvironment are central to the maintenance of immune homeostasis (Murray,

252 2016). Amino acid insufficiency will cause depletion of available aminoacylated

253 tRNA, which is essential for the host to sense amino acid limitation and immune

response (Brown et al., 2016, 2010; Harding et al., 2003). A recent study on several

255 mammalian cell models reported that when aminoacyl-tRNA synthetase was inhibited,

11

the cytokine stimulated proinflammatory response would be substantially suppressed, 256 and a single amino acid depletion, such as arginine or histidine, could also suppress 257 the cytokine induced immune response (Kim et al., 2020). Thus the identified 258 pathways regulating in aminoacyl-tRNA biosynthesis and arginine biosynthesis may 259 be both involved in the inflammatory response. Additionally, arginine and BCAAs 260 (i.e., valine, leucine and isoleucine), were also reported regulating innate and adaptive 261 immune responses and enhancing intestinal development (Zhang et al., 2017). 262 263 Collectively, these key roles that amino acids play in the immunoregulation may help explain how the PRS-related core OTUs modulate host inflammation via amino acid 264 metabolism. Furthermore, given the high expression of ACE2 in the ileum and colon, 265 and the role of ACE2 as a key regulator of dietary amino acid homeostasis and innate 266 immunity (Hashimoto et al., 2012; Zhang et al., 2020), ACE2 may be another key 267 mediator between gut microbiota and host inflammation. However, whether and how 268 ACE2 may mediate the association between gut microbiota and COVID-19 severity 269 warrants further mechanistic study. 270

271

We observed that several host demographic and clinical factors had a strong effect on 272 the identified core OTU composition, among which drug use and metabolic 273 phenotypes had been widely reported correlating with gut microbiome composition 274 (Cabreiro et al., 2013; Gilbert et al., 2018; Vich Vila et al., 2020). Although these 275 observations were quite crude, it gave us an overview of the potential influence of 276 host and environmental factors on the PRS-related gut microbiota matrix. Those 277 known factors contributed to the COVID-19 susceptibility also contributed to the 278 279 variance of the gut microbiota, including age, sex, and indicators of clinical comorbidities (blood pressure, glucose triglycerides, high-density and low-density 280 lipoprotein cholesterol, and diabetes medication). 281

282

283 In summary, our study provides novel insight that gut microbiota may underlie the

susceptibility of the healthy individuals to the COVID-19. In the global crisis of

285 COVID-19, a wide disparity in the susceptibility of the disease or disease progression

12

286	has been observed. Our results provide important evidence and suggestions about the
287	potential biological mechanism behind the diverse susceptibility among different
288	groups of people. The discovered core gut microbial features and related metabolites
289	may serve as a potential preventive/treatment target for intervention especially among
290	those who are susceptible to the SARS-CoV-2 infection. They could also serve as
291	potential therapeutic targets for drug development.
292	

293 Acknowledgements

- 294 This study was funded by the National Natural Science Foundation of China
- 295 (81903316, 81773416, 81972492, 21904107, 81672086), Zhejiang Ten-thousand
- 296Talents Program (101396522001), Zhejiang Provincial Natural Science Foundation
- for Distinguished Young Scholars (LR19C050001), the 5010 Program for Clinical
- 298 Researches (2007032) of the Sun Yat-sen University, Hangzhou Agriculture and
- 299 Society Advancement Program (20190101A04), and Tencent foundation (2020). The
- 300 funder had no role in study design, data collection and analysis, decision to publish, or
- 301 writing of the manuscript. We thank Dr. C.R. Palmer for his invaluable comments to
- 302 this study; and Westlake University Supercomputer Center for assistance in data
- 303 storage and computation; and all the patients who consented to donate their clinical
- 304 information and samples for analysis; and all the medical staff members who are on
- the front line fighting against COVID-19.
- 306

307 Author Contributions

- 308 Conceptualization, J.S.Z.; Methodology, W.G. and Y.F.; Formal Analysis, W.G., Y.F.,
- 309 L.Y., G.D.C, X.C., M.S., and F.X.; Investigation, M.L.X., B.S, X.W., H.Z., and
- 310 W.H.L.; Data curation, X.Y., H.C., Y.Z., Z.J., Z.M. and C.X.; Resources, Y.M.C.,
- 311 T.G., J.S.Z; Writing, Y.F. and J.S.Z.; Writing-Review & Editing, J.S.Z, T.G., J.W,
- 312 Y.F. and W.L.G; Visualization, M.S. and F.X.; Supervision, J.S.Z., Y.M.C., and T.G.;
- 313 Funding Acquisition, J.S.Z., Y.M.C. and T.G.

314 **Declaration of Interests**

315 The authors declare no competing financial interests

316	Figure	Legends
	0	0

310	rigure Legenus
317	Figure 1. Study design and analysis pipeline. Study overview. 1) constructing a
318	novel COVID-19 blood proteomic risk score (PRS) among 31 COVID-19 patients (18
319	non-severe cases and 13 severe cases). 2) Applicating the PRS in healthy participants,
320	and further linking it to host inflammatory status (n=990). 3) Investigating the
321	potential role of gut microbiota in predicting the PRS of COVID-19 based on a
322	machine-learning method (n=301). 4) Assessing the relationships between the
323	PRS-related gut microbiota and inflammatory factors (n=336). 5) Fecal metabolomics
324	analysis reveals function of gut microbiota on host metabolism (n=987). 6)
325	Investigating the impact of host and environmental factors on PRS-related core
326	microbial OTUs (n=1729).
327	
328	Figure 2. Predictive proteomic profile for severe COVID-19 is correlated with
329	pro-inflammatory factors among healthy individuals. (A) The associations of
330	COVID-19-related blood proteomic biomarkers and proteomic risk score (PRS) with
331	host inflammatory markers. 990 participants were involved in this analysis. # protein
332	down-regulated in severe patients, else, up-regulated.
333	(B) The correlation of the above blood proteomic biomarkers and PRS with host
334	inflammatory markers stratified by the median age of participants (<58 years or \geq 58
335	years). The color of the heatmap indicates the Spearman correlation coefficients
336	(blue-negative, red-positive). (C) The correlation of the PRS with individual host
337	inflammatory markers stratified by the median age of participants (<58 years or \geq 58
338	years).
339	
340	Figure 3. Core microbiota features predict COVID-19 proteomic risk score (PRS)
341	and host inflammation. (A) Plots of out-of-sample predicted PRS versus actual PRS
342	based on top 20 ranked OTUs or demographic/clinical factors (age, sex BMI, fasting
343	glucose, HDL, LDL, TC, TG, DBP, and SBP) using LightGBM with 10-fold
344	cross-validation. The plots in the first row indicate the model performance among
345	cross-sectional subset of individuals (n=132); the plots in the second row indicate the

346	model performance among prospective subset of individuals (n=169). The mean R^2
347	across the 10 cross validations, Pearson r of predicted values versus actual values, and
348	corresponding P-value are shown in the figures. (B) The correlation of the core
349	microbial OTUs and host inflammatory cytokines (n=336). The color of the heatmap
350	indicates the Spearman correlation coefficients (blue-negative, red-positive).
351	
352	Figure 4. Fecal metabolome may be the key to link the proteomic risk
353	score-related core microbial features and host inflammation
354	(A) Associations of the core microbial OTUs with fecal metabolites (n=987). The
355	relationships between microbial OTUs and fecal metabolites was assessed by a linear
356	regression model adjusting for age, sex, BMI. Multiple testing was adjusted using
357	Benjamini and Hochberg method, with a false discovery rate (FDR) of <0.05 being
358	considered statistically significant. We only presented metabolites showing significant
359	associations with more than half of the core microbial OTUs (n=20) in the figure.
360	Sizes of the nodes represent the number of OTUs related with fecal metabolites. Red
361	edge, β -coefficient >0; blue edge, β -coefficient <0. (B) Pathway analysis for the core
362	fecal metabolites (shown in part A) using MetaboAnalyst 4.0 (Chong et al., 2019). (C)
363	Metabolites enriched in the significant pathways (shown in part B).
364	
365	Figure 5. Host and environmental factors modulate the blood proteomic risk
366	score-related core microbial OTUs. Host and environmental factors including 18
367	demographic/clinical items and 22 dietary/nutritional items were used in this analysis
368	(n=1729). The bar plot indicates the explained variation of the core OTUs
369	composition (Bray-Curtis distance) by each item. The heatmap next to the bar plot
370	shows the correlation coefficients of each item with the core OTUs.
371	

15

372 STAR MEHTODS

373 **RESOURCE AVAILABILITY**

- 374 Lead Contact
- 375 Further information and requests for resources and reagents should be directed to and
- will be fulfilled by the Lead Contact, Ju-Sheng Zheng
- 377 (zhengjusheng@westlake.edu.cn).
- 378
- 379 Materials Availability
- 380 This study did not generate new unique reagents.
- 381

382 Data and Code Availability

- 383 The raw data of 16 S rRNA gene sequences are available at CNSA
- 384 (https://db.cngb.org/cnsa/) of CNGBdb at accession number CNP0000829.
- 385

386 SUBJECT DETAILS

387 COVID-19 proteomics data set

388 Detailed information about the COVID-19 patients and proteomics data set is

described in our recent publication (Shen et al., 2020). Briefly, the proteome of sera

from 46 COVID-19 patients and 53 control samples from Taizhou Public Health

391 Medical Center were analyzed by TMTpro 16 plex-based quantitative proteomics

technology. All the patients were diagnosed between January 23 and February 4, 2020.

393 According to the Chinese Government Diagnosis and Treatment Guideline for

COVID-19, the COVID-19 patients were classified into four groups, (1) mild (mild

395 symptoms without pneumonia); (2) typical (fever or respiratory tract symptoms with

396 pneumonia); (3) severe (fulfill any of the three criteria: respiratory distress,

respiratory rate \ge 30 times/min; mean oxygen saturation \le 93% in resting state;

arterial blood oxygen partial pressure/oxygen concentration \leq 300mmHg); and (4)

399 critical (fulfill any of the three criteria: respiratory failure and require mechanical

400 ventilation; shock incidence; admission to ICU with other organ failure). We treated

16

401 mild and typical patients as a non-severe COVID-19 group, and the others a severe

402 COVID-19 group.

403

404 *Healthy subjects, sample collection, and clinical metadata*

405 In the present study, the healthy (non-infected) subjects are from the

406 community-based Guangzhou Nutrition and Health Study (GNHS), and the detailed

407 study designs of GNHS have been reported previously (Zhang et al., 2014). Briefly,

408 participants were enrolled between 2008 and 2013, and followed up to May 2018.

409 Blood samples were collected at enrollment and follow-up visits, and stool samples

410 were collected only during follow-up visits. All the blood samples were collected as

411 venous whole blood in the early morning before diet using serum separation tubes.

412 The blood samples were centrifuged at 3,500 rpm for 10 min for serum collection.

413 The serum samples were frozen at -80°C. The stool samples were collected at a local

study site within the School of Public Health at Sun Yat-sen University, and were

415 transferred to a -80°C facility within 4 hours after collection.

416

417 Demographic and lifestyle factors were all collected by questionnaire during on-site
418 face-to-face interviews. Habitual dietary intakes over the past 12 months were

assessed by a food frequency questionnaire, as previously described (Zhang CX,

420 2009). Physical activity was assessed as a total metabolic equivalent for task (MET)

421 hours per day on the basis of a validated questionnaire for physical activity (Liu et al.,

422

2001).

423

Anthropometric factors were measured by trained nurses on site during the baseline
interview. Fasting venous blood samples were taken at each recruitment or follow-up
visit. Serum low-density lipoprotein cholesterol and glucose were measured by
coloimetric methods using a Roche Cobas 8000 c702 automated analyzer (Roche
Diagnostics GmbH, Shanghai, China). Intra-assay coefficients of variation (CV) was
2.5% for glucose. Insulin was measured by electrochemiluminescence immunoassay
(ECLIA) methods using a Roche cobas 8000 e602 automated analyzer (Roche

17

431	Diagnostics	GmbH,	Shanghai,	China)	. High-perform	mance liquid	chromatography was
-----	-------------	-------	-----------	--------	----------------	--------------	--------------------

432 used to measure glycated hemoglobin (HbA1c) using the Bole D-10 Hemoglobin A1c

- 433 Program on a Bole D-10 Hemoglobin Testing System, and the intraassay CV was
- 434 0.75%.
- 435

436 *Ethics*

- 437 This study has been approved by the Ethical/Institutional Review Board of Taizhou
- 438 Public Health Medical Center, the Ethics Committee of the School of Public Health at
- 439 Sun Yat-sen University and Ethics Committee of Westlake University.
- 440

441 METHOD DETAILS

- 442 Proteomic analysis
- 443 1 μL of serum sample from each patient was analyzed using proteomics technology.
- 444 The serum was firstly denatured with 20 μL of buffer containing 8 M urea (Sigma,
- 445 #U1230) in 100 mM ammonium bicarbonate at 30°C for 30 min. The lysates were
- reduced with 10 mM tris (2-carboxyethyl) phosphine (TCEP, Sigma #T4708) at room
- temperature for 30 min, and were then alkylated with 40 mM iodoacetamide (IAA,
- 448 Sigma, #SLCD4031) in darkness for 45 min. The solution was then diluted with 70
- μ L 100 mM ammonium bicarbonate to make sure urea concentration is less than 1.6M,
- 450 and was subjected to two times of tryptic digestion (Hualishi Tech. Ltd, Beijing,
- 451 China), each step with 2.5 μ L trypsin (0.4 μ g/ μ L), at 32°C for 4 hr and 12 hr,
- 452 respectively. Thereafter, the solution was acidified with 1% trifluoroacetic (TFA)
- 453 (Thermo Fisher Scientific, #T/3258/PB05) to pH 2–3 to stop the reaction. Peptides
- 454 were cleaned using C18 (Thermo, #60209-001).

- 456 Peptide samples were then injected for LC-MS/MS analysis using an Eksigent
- 457 NanoLC 400 System (Eksigent, Dublin, CA, USA) coupled to a TripleTOF 5600
- 458 system (SCIEX, CA, USA). Briefly, peptides were loaded onto a trap column (5 μm,
- 459 120 Å, 10×0.3 mm), and were separated along a 20 min LC gradient (5–32%)

18

460	buffer B, 98% ACN, 0.1% formic acid in HPLC water; buffer A: 2% ACN, 0.1%
461	formic acid in HPLC water) on an analytical column (3 $\mu m,$ 120 Å, 150 \times 0.3 mm) at
462	a flow rate of 5 μ L/min. The SWATH-MS method is composed of a 100 ms of full
463	TOF MS scan with the acquisition range of 350-1250 m/z , followed by MS/MS scans
464	performed on all precursors (from 100 to 1500 Da) in a cyclic manner (Gillet et al.,
465	2012). A 55-variable-Q1 isolation window scheme was used in this study. The
466	accumulation time was set at 30 ms per isolation window, resulting in a total cycle
467	time of 1.9 s.
468	
469	After SWATH acquisition, the Wiff files were converted into mzXML format using
470	msconvert (ProteoWizard 3.0) (Kessner et al., 2008) and analyzed using OpenSWATH
471	(2.1) (Kessner et al., 2008) against a pan human spectral library (Kessner et al., 2008)
472	that contains 43899 peptide precursors and 1667 unique Swiss-Prot proteins protein
473	groups. The retention time extraction window was set at 120 seconds, and the m/z
474	extraction was performed with 30 ppm tolerance. Retention time was then calibrated
475	using Common internal Retention Time standards (CiRT) peptides (Kessner et al.,
476	2008). Peptide precursors were identified by OpenSWATH (version 2.0) and
477	pyprophet (version 0.24) with FDR<0.01 to quantify the proteins in each sample.
478	
479	Measurement of inflammatory biomarkers
480	For samples collected at baseline, Human FlowCytomix (Simplex BMS8213FF and
481	BMS8288FF, eBioscience, San Diego, CA, USA) and the Human Basic Kit
482	FlowCytomix (BMS8420FF, eBioscience, San Diego, CA, USA) on a BD
483	FACSCalibur instrument (BD Biosciences, Franklin Lakes, NJ, USA) were used for
484	the measurements of serum tumor necrosis factor (TNF- α), Interleukin-6 (IL-6), and
485	Interleukin-1 β (IL-1 β). High-sensitivity CRP was measured using a [Cardiac
486	C-Reactive Protein (Latex) High Sensitive (CRPHS) kit], and detected on a Cobas
487	c701 automatic analyzer. The between-plate CVs were 14.1% for MCP1, 6.6% for

488 TNF-α, 2.5% for IL-6, and 10.2% for IL-1β.

19

490	For samples collected during follow-up visits, serum cytokine levels were assessed by
491	electrochemiluminescence based immunoassays using the MSD V-Plex
492	Proinflammatory Panel 1 (human) kit. 50 μ L of serum derived from whole blood by
493	centrifugation (10 min,3,500 rpm) was processed according to the manufacturer's
494	instructions. Briefly, the serum was diluted at a minimum of 2-fold dilution at first,
495	while the detection antibodies were combined and added to 2400 μ L of diluent.
496	Thereafter, wash buffer and read buffer T were prepared as instructed. After finishing
497	washing and adding samples, washing and adding detection antibody solution and
498	washing plates again, then the plate could be analyzed on an MSD instrument.
499	Accuracy and precision are evaluated by measuring calibrators across multiple runs
500	and multiple lots. Intra-run coefficient of variations (CVs) are typically below 7% and
501	inter-ran CVs are typically below 15%. In the present study, the inters-run CVs of
502	calibrators were 2.2% for IL-1 β , 2.5% for IL-2, 1.6% for IL-4, 1.7 for IL-6, 3.6 for
503	IL-8, 2.5 for 1.3% for IL-10, 1.1% for IL-12p70, 0.87% for IL-13, TNF- α , 2.0% for
504	IFN-γ.
505	

506 Microbiome analysis ---- DNA extraction

- 507 Total bacterial DNA was extracted using the QIAamp® DNA Stool Mini Kit (Qiagen,
- 508 Hilden, Germany) following the manufacturer's instructions. DNA concentrations
- 509 were measured using the Qubit quantification system (Thermo Scientific, Wilmington,
- 510 DE, US). The extracted DNA was then stored at -20 °C.
- 511

512 *Microbiome analysis ---- 16S rRNA gene amplicon sequencing*

- 513 The 16S rRNA gene amplification procedure was divided into two PCR steps, in the
- 514 first PCR reaction, the V3-V4 hypervariable region of the 16S rRNA gene was
- amplified from genomic DNA using primers 341F(CCTACGGGNGGCWGCAG) and
- 516 805R(GACTACHVGGGTATCTAATCC). Amplification was performed in 96-well
- 517 microtiter plates with a reaction mixture consisting of 1X KAPA HiFi Hot start Ready
- 518 Mix, 0.1µM primer 341 F, 0.1 µM primer 805 R, and 12.5 ng template DNA giving a
- total volume of 50 μL per sample. Reactions were run in a T100 PCR thermocycle

20

520 (BIO-RAD) according to the following cycling program: 3 min of denaturation at 94 °C, followed by 18 cycles of 30 s at 94 °C (denaturing), 30 s at 55 °C (annealing), 521 and 30 s at 72 °C (elongation), with a final extension at 72 °C for 5 min. Subsequently, 522 the amplified products were checked by 2% agarose gel electrophoresis and ethidium 523 bromide staining. Amplicons were quantified using the Qubit quantification system 524 (Thermo Scientific, Wilmington, DE, US) following the manufacturers' instructions. 525 Sequencing primers and adaptors were added to the amplicon products in the second 526 527 PCR step as follows 2 µL of the diluted amplicons were mixed with a reaction solution consisting of 1×KAPA HiFi Hotstart ReadyMix, 0.5µM fusion forward and 528 0.5μ M fusion reverse primer, 30 ng Meta-gDNA(total volume 50 μ L). The PCR was 529 run according to the cycling program above except with cycling number of 12. The 530 531 amplification products were purified with Agencourt AMPure XP Beads (Beckman Coulter Genomics, MA, USA) according to the manufacturer's instructions and 532 quantified as described above. Equimolar amounts of the amplification products were 533 pooled together in a single tube. The concentration of the pooled libraries was 534 535 determined by the Qubit quantification system. Amplicon sequencing was performed on the Illumina MiSeq System (Illumina Inc., CA, USA). The MiSeq Reagent Kits v2 536 (Illumina Inc.) was used. Automated cluster generation and 2×250 bp paired-end 537 sequencing with dual-index reads were performed. 538

539

540 *Microbiome analysis ---- 16S rRNA gene sequence data processing*

Fastq-files were demultiplexed by the MiSeq Controller Software (Illumina Inc.). The 541 sequence was trimmed for amplification primers, diversity spacers, and sequencing 542 543 adapters, merge-paired and quality filtered by USEARCH. UPARSE was used for OTU clustering equaling or above 97%. Taxonomy of the OTUs was assigned and 544 sequences were aligned with RDP classifier. The OTUs were analyzed by 545 phylogenetic and operational taxonomic unit (OTU) methods in the Quantitative 546 Insights into Microbial Ecology (QIIME) software version 1.9.0 (Caporaso et al., 547 2010). 548

550 Metabolomic analysis ---- sample preparation and instrumentation

Targeted metabolomics approach was used to analyze fecal samples, with a total of 551 552 198 metabolites quantified. Feces samples were thawed on ice-bath to diminish degradation. About 10mg of each sample was weighed and transferred to a new 553 1.5mL tube. Then 25µL of water was added and the sample was homogenated with 554 555 zirconium oxide beads for 3 minutes. 185µL of ACN/Methanol (8/2) was added to extract the metabolites. The sample was centrifuged at 18000g for 20 minutes. Then 556 557 the supernatant was transferred to a 96-well plate. The following procedures were performed on a Biomek 4000 workstation (Biomek 4000, Beckman Coulter, Inc., 558 Brea, California, USA). 20µL of freshly prepared derivative reagents was added to 559 each well. The plate was sealed and the derivatization was carried out at 30°C for 60 560 min. After derivatization, 350µL of ice-cold 50% methanol solution was added to 561 dilute the sample. Then the plate was stored at -20°C for 20 minutes and followed by 562 4000g centrifugation at 4 °C for 30 minutes. 135µL of supernatant was transferred to 563 a new 96-well plate with 15μ L internal standards in each well. Serial dilutions of 564 565 derivatized stock standards were added to the left wells. Finally the plate was sealed for LC-MS analysis. 566

567

An ultra-performance liquid chromatography coupled to tandem mass spectrometry 568 (UPLC-MS/MS) system (ACQUITY UPLC-Xevo TQ-S, Waters Corp., Milford, MA, 569 USA) was used to quantitate the microbial metabolite in the present study. The 570 optimized instrument settings are briefly described below. ACQUITY UPLC BEH 571 C18 1.7 µM VanGuard pre-column (2.1×5 mm) and ACQUITY UPLC BEH C18 1.7 572 573 μ M analytical column (2.1 × 100 mm) were used. The column temperature was 40°C 574 and sample manager temperature was 10°C. Mobile phase A was water with 0.1% formic acid, and B was acetonitrile / IPA (90:10). The gradient conditions were as 575 follows: 0-1 min (5% B), 1-12 min (5-80% B), 12-15 min (80-95% B), 15-16 min 576 (95-100%B), 16-18 min (100%B), 18-18.1 min (100-5% B), 18.1-20 min (5% B), at a 577 flow rate of 0.40 mL/min. The capillary of mass spectrometer were 1.5 (ESI+) and 2.0 578 (ESI-), while the source temperature and desolvation temperature was 150°C and 579

22

580	550°C, respective	ly. The deso	lvation gas flow v	vas 1000 L/hour.
-----	-------------------	--------------	--------------------	------------------

581

582 *Metabolome analysis ---- Analytical quality control procedures*

583 The rapid turnover of many intracellular metabolites makes immediate metabolism

quenching necessary. The extraction solvents are stored in -20°C freezer overnight

and added to the samples immediately after the samples were thawed. We use ice-salt

bath to keep the samples at a low temperature and minimize sample degradation

during sample preparation. All the prepared samples should be analyzed within 48

588 hours after sample extraction and derivatization.

589

A comprehensive set of rigorous quality control/assurance procedures is employed to
ensure a consistently high quality of analytical results, throughout controlling every

single step from sample receipt at laboratory to final deliverables.

593 The ultimate goal of QA/QC is to provide the reliable data for biomarker discovery 594 study and/ or to aid molecular biology research. To achieve this, three types of quality 595 control samples i.e., test mixtures, internal standards, and pooled biological samples 596 are routinely used in the metabolomics platform. In addition to the quality controls, 597 conditioning samples, and solvent blank samples are also required for obtaining 598 optimal instrument performance.

599

600 Test mixtures comprise a group of commercially available standards with a mass

range across the system mass range used for the study samples. These samples were

analyzed at the beginning and end of each batch run to ensure that the instruments

603 were performing within laboratory specifications (retention time stability,

604 chromatographic peak shape, and peak signal intensity). The retention time shift

should be within 4 sec. and the difference of peak intensity should be within 15% for

606 LC-MS.

607

608 Internal standards were added to the test samples in order to monitor analytical

609 variations during the entire sample preparation and analysis processes. The Pooled

23

610	QC samples were prepared by mixing aliquots of the study samples such that the
611	pooled samples broadly represent the biological average of the whole sample set. The
612	QC samples for this project were prepared with the test samples and injected at
613	regular intervals (after every 14 test samples for LC-MS) throughout the analytical
614	run.
615	
616	Reagent blank samples are a mixture of solvents used for sample preparation and
617	are commonly processed using the same procedures as the samples to be analyzed.
618	The reagent blanks serve as a useful alert to systematic contamination. As the reagent
619	blanks consist of high purity solvents and are analyzed using the same methods as the
620	study samples, they are also used to wash the column and remove cumulative matrix
621	effects throughout the study.
622	
623	The calibrators consist of a blank sample (matrix sample processed without
624	internal standard), a zero sample (matrix sample processed with internal standard),
625	and a series of seven concentrations covering the expected range for the metabolites
626	present in the specific biological samples. LLOQ and ULOQ are the lowest and
627	highest concentration of the standard curve that can be measured with acceptable
628	accuracy and precision.
629	
630	To diminish analytical bias within the entire analytical process, the samples were
631	analyzed in group pairs but the groups were analyzed randomly. The QC samples,
632	calibrators, and blank samples were analyzed across the entire sample set.
633	
634	Metabolome analysisSoftware and quantitation
635	The raw data files generated by UPLC-MS/MS were processed using the
636	QuanMET software (v2.0, Metabo-Profile, Shanghai, China) to perform peak
637	integration, calibration, and quantification for each metabolite. The current QuanMET

638 is hosted on Dell PowerEdge R730 Servers operated with Linux Ubuntu 16.10 OS.

639	The secured Java	UI (User Interface	e) permits the use	er have access to	use a great

- 640 variety of statistical tools for viewing and exploring project data.
- 641
- 642 Mass spectrometry-based quantitative metabolomics refers to the determination
- of the concentration of a substance in an unknown sample by comparing the unknown
- to a set of standard samples of known concentration (i.e., calibration curve). The
- calibration curve is a plot of how the analytical signal changes with the concentration
- of the analyte (the substance to be measured). For most analyses a plot of instrument
- response vs. concentration will show a linear relationship and the concentration of the
- 648 measured samples were calculated.
- 649

650 STATISTICAL ANALYSIS

- 651 Dataset at each step of analyses among the healthy individuals from Guangzhou
- 652 Nutrition and Health Study

Dataset 1 (n=990): data from the baseline of GNHS. A total of 990 subjects with measurement of serum proteomics at baseline of the GNHS cohort were included in the initial discovery cohort. Among this initial discovery cohort, 455 subjects had data of serum IL-1β and IL-6, 456 subjects had data of serum TNF- α , and 953 subjects had serum hsCRP data. These data were used to investigate the relationship between the PRS and host inflammatory status.

659

660 Dataset 2 (n=301): data from a follow-up visit of GNHS. A sub-cohort of 301

661 participants with measurement of both gut microbiota (16s rRNA) and blood

proteomics data. Gut microbiota data were collected and measured during a follow-up

visit of the cohort participants, with a cross-sectional subset of the individuals (n=132)

- having blood proteomic data at the same time point as the stool collection and another
- 665 independent prospective subset of the individuals (n=169) having proteomic data at a
- next follow-up visit \sim 3 years later than the stool collection. Data from these subjects
- 667 were used to explore the predictive capacity of the gut microbiota for PRS.
- 668

669	Dataset 3 (n=366): data from a follow-up visit of GNHS. Independent from the
670	above 301 subjects in dataset 2, there were additionally 336 subjects with both fecal
671	16s rRNA sequencing and serum inflammatory cytokines data, at the same time point
672	during follow-up. The data from these 336 subjects were used to examine the
673	relationships between the core OTUs and 10 host inflammatory cytokines.
674	
675	Dataset 4 (n=987): data from a follow-up visit of GNHS. A total of 987 individuals
676	had received fecal metabolomics and fecal microbiome examination at the same time
677	point during the follow-up visit. These subjects were included in the analysis to assess
678	the relationships between the core gut microbiota and fecal metabolomics.
679	
680	Dataset 5 (n=1729): data from a follow-up visit of GNHS. In total, 1729 participants
681	finished food frequency questionnaire, demographic questionnaire and medical
682	examination, and provided stool samples during follow-up. Thus, this subset of 1729
683	subjects were included to test how the dietary habits, lifestyle and health status
684	influence the gut microbiota composition.
685	
686	In summary, a sum of 2413 healthy non-infected individuals are involved in the
687	present study, which mainly consists of a subset of subjects with proteomic data at
687 688	baseline ($n=990$) and a subset of subjects with gut microbiome and metabolome data
688	baseline (n=990) and a subset of subjects with gut microbiome and metabolome data
688 689	baseline (n=990) and a subset of subjects with gut microbiome and metabolome data
688 689 690	baseline (n=990) and a subset of subjects with gut microbiome and metabolome data at a follow-up visit (n=2172, within which 301 individuals also had proteomic data).
688 689 690 691	baseline (n=990) and a subset of subjects with gut microbiome and metabolome data at a follow-up visit (n=2172, within which 301 individuals also had proteomic data). <i>Data imputation and presentation</i>
688 689 690 691 692	 baseline (n=990) and a subset of subjects with gut microbiome and metabolome data at a follow-up visit (n=2172, within which 301 individuals also had proteomic data). Data imputation and presentation Missing values in proteomic features were imputed with 50% of the minimal value.
688 689 690 691 692 693	baseline (n=990) and a subset of subjects with gut microbiome and metabolome data at a follow-up visit (n=2172, within which 301 individuals also had proteomic data). <i>Data imputation and presentation</i> Missing values in proteomic features were imputed with 50% of the minimal value. Data are presented as mean \pm SD or percentage as indicated. Statistical tests used to
688 689 690 691 692 693 694	baseline (n=990) and a subset of subjects with gut microbiome and metabolome data at a follow-up visit (n=2172, within which 301 individuals also had proteomic data). <i>Data imputation and presentation</i> Missing values in proteomic features were imputed with 50% of the minimal value. Data are presented as mean \pm SD or percentage as indicated. Statistical tests used to compare conditions are indicated in figure legends. Unless otherwise stated, statistical
688 689 690 691 692 693 694 695	baseline (n=990) and a subset of subjects with gut microbiome and metabolome data at a follow-up visit (n=2172, within which 301 individuals also had proteomic data). <i>Data imputation and presentation</i> Missing values in proteomic features were imputed with 50% of the minimal value. Data are presented as mean \pm SD or percentage as indicated. Statistical tests used to compare conditions are indicated in figure legends. Unless otherwise stated, statistical analysis was performed using Python 3.7, R software (version 3.6.1, R foundation for

26

699 Construction of proteomic risk score (PRS)

700 We used 20 out of 22 previously identified proteomic biomarkers to construct a

proteomic risk score (PRS) for severe COVID-19 in COVID-19 patients and healthyparticipants.

703
$$PRS_i = \sum_{j=1}^{20} \beta_j x_{ij}$$

Where, PRS_i is a proteomic risk score for individual *i*, 20 is the number of proteins involved the score construction, x_{ij} is the Z score of abundance of the protein *j* for individual *i*. β is 1 or -1 depending on the association between the protein *j* and risk of

progressing to clinically severe phase (1, up-regulated in severe patients, -1,

- 708 down-regulated in severe patients).
- 709

```
Association of PRS with the risk of progressing to clinically severe phase
```

711 Poisson regression model was used to examine the association of PRS with the risk of

712 progressing to clinically severe phase among 31 COVID-19 patients (18 non-severe

713 patients; 13 severe patients), adjusting for age, sex and BMI.

714

715 Correlation between PRS and pro-inflammatory biomarkers

716 Spearman correlation analysis was used to examine the correlation between PRS and

pro-inflammatory biomarkers (i.e., hsCRP, IL-1 β , IL-6 and TNF- α). p<0.05 was

- 718 considered as statistically significant.
- 719

720 Machine learning algorithms for identifying microbial features to predict PRS

721 A 10-fold cross-validation (CV) implementation of gradient boosting framework

722 —LightGBM and SHAP (Shapley Additive exPlanations) was used to link input gut

- microbial features with PRS (Ke et al., 2017; Lee, 2017). A 10-fold CV predict
- implementation was used to generate a OTU-predicted PRS value for each participant.
- In this approach, each LightGBM model is trained on 90% of the cohort with 10-fold
- 726 CV, and PRS is predicted for the 10% of the participants who were not used for model
- 727 optimization. This process is repeated ten-fold resulting in a test PRS set for each

728	participant and ten different average absolute SHAP value for each OTUs. The top 20
729	ranked OTUs based the sum of the average absolute SHAP value across ten-fold were
730	included in further analysis. The R ² score was computed by taking the mean of all the
731	R ² scores across the 10 out-of-sample predictions. Pearson r was calculated using
732	actual PRS and predicted PRS for the entire cohort. We also compared the predictive
733	performance for the top 20 ranked OTUs, demographic characteristics and laboratory
734	tests (age, BMI, sex, blood pressure and blood lipids). Our predictor is based on code
735	adapted from the sklearn 0.15.2 lightgbm regression (Pedregosa et al., 2011).
736	
737	The relationship between the identified core OTUs and host inflammatory cytokines
738	Spearman correlation analysis was used to examine the correlation between PRS and
739	cytokines (i.e., IL-1 β , IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, TNF- α and
740	IFN- γ). p<0.05 was considered as statistically significant.
741	
742	Relationship between OTUs and fecal metabolites
743	Prior to the analysis, we excluded the participants with T2D medication use, and all
744	fecal metabolites were natural logarithmic transformed to reduce skewness of traits
745	distributions. Similarly, to reduce skewness of the distribution of microbial taxa
746	counts, we first added 1 to all OTUs and then performed natural log transformation.
747	The relationship between fecal metabolites and microbial OTUs was assessed by
748	linear regression analysis while adjusting for age, sex, BMI. Multiple testing was
749	adjusted using Benjamini and Hochberg method, with a false discovery rate (FDR) of
750	<0.05 being considered statistically significant. Metabolites showed significant
751	associations with more than half of the selected microbial OTUs, were used for
752	subsequent pathway analysis using MetaboAnalyst 4.0 (Chong et al., 2019).
753	
754	Associations of host and environmental factors with gut microbial features
755	We assessed how many variations in the identified core OTUs composition
756	(Bray-Curtis distance) can be explained by host and environmental factors (40 factors)

757	using the function adonis fr	om the R package v	vegan. The p value was	s determined by

- 758 1000x permutations. The total variation explained was also calculated per category
- 759 (demographic/clinical category and dietary/nutritional factors) and for all factors
- 760 together. Spearman correlation analysis was used to assess the potential effect of each
- 761 factor on each of the core OTU. Multiple testing was adjusted using Benjamini and
- Hochberg method, with a false discovery rate (FDR) of <0.05 being considered
- 763 statistically significant.
- 764

29

765 Supplementary Figure Legends

/65	Supplementary Figure Legenus
766	Figure S1. Timeline of the participants enrollment, follow-up visit and sample
767	collection in the Guangzhou Health and Nutrition Study. (A) At baseline, 4048
768	subjects provided completed metadata (required for analysis in the present study), and
769	1114 subjects provided blood samples (1114 for proteomic analysis and 990 for
770	measurement of inflammatory factors). At follow-up visit, 2172 subjects provided
771	stool samples (n=1729 for 16s rRNA sequencing; n=987 for metabolomic analysis),
772	among which 667 subjects provided blood samples (n=301 for proteomic analysis;
773	n=366 for measurement of inflammatory factors). (B) Detail information about the
774	number of participants in the dataset1-dataset4 used in the present study. (C) Detail
775	information about the number of participants in the dataset5 used in the present study.
776	
777	Figure S2. The correlation of the blood proteomic biomarkers and PRS with host
778	inflammatory markers stratified by sex (n=990). The color of the heatmap
779	indicates the Spearman correlation coefficients (blue-negative, red-positive). # protein
780	down-regulated in severe patients, else, up-regulated.
781	
782	Figure S3. Co-variation of the core OTUs abundance and predictive proteomic
783	biomarkers of COVID-19 (n=132). Co-inertia analysis of the relationship between
784	20 identified OTUs and 20 predictive proteomic biomarkers among a cross-sectional
785	subset of 132 individuals. Each sample is represented with an arrow. The sample
786	projection in the OTUs and the proteomic biomarkers space are represented by the
787	starting point and the end of the arrow, respectively. Length of the arrow represents
788	distance between the projections. (A, overall; B, age \geq 58; C, age $<$ 58).
789	Second and the second
790 791	Supplementary Tables Table S1. Characteristics of the data analysis sets
792	Table S1. Characteristics of the data analysis sets Table S2. List of the 20 proteomic biomarkers integrated in the proteomic risk
793	score
794	Table S3. List and taxonomic classifications of the PRS-related core microbial
795	OTUs
796	

797 **References**


- Belkaid, Y., and Hand, T.W. (2014). Role of the microbiota in immunity and
- 799 inflammation. Cell 157, 121–141.
- Brown, A., Fernández, I.S., Gordiyenko, Y., and Ramakrishnan, V. (2016).
- Ribosome-dependent activation of stringent control. Nature 534, 277–280.
- Brown, M. V, Reader, J.S., and Tzima, E. (2010). Mammalian aminoacyl-tRNA
- 803 synthetases: cell signaling functions of the protein translation machinery. Vascular
- 804 Pharmacology 52, 21–26.
- 805 Cabreiro, F., Au, C., Leung, K.-Y., Vergara-Irigaray, N., Cochemé, H.M., Noori, T.,
- 806 Weinkove, D., Schuster, E., Greene, N.D.E., and Gems, D. (2013). Metformin retards
- aging in C. elegans by altering microbial folate and methionine metabolism. Cell *153*,
 228–239.
- 809 Cani, P.D., and Jordan, B.F. (2018). Gut microbiota-mediated inflammation in obesity:
- a link with gastrointestinal cancer. Nature Reviews. Gastroenterology & Hepatology
- 811 *15*, 671–682.
- 812 Caporaso, J.G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F.D., Costello,
- E.K., Fierer, N., Peña, A.G., Goodrich, K., Gordon, J.I., et al. (2010). QIIME allows
- analysis of high-throughput community sequencing data. Nat Methods 7, 335–336.
- 815 Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y.,
- 816 Wei, Y., et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019
- novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London,
 England) *395*, 507–513.
- 819 Chong, J., Wishart, D.S., and Xia, J. (2019). Using MetaboAnalyst 4.0 for
- 820 Comprehensive and Integrative Metabolomics Data Analysis. Current Protocols in821 Bioinformatics 68, e86.
- 822 Cole-Jeffrey, C.T., Liu, M., Katovich, M.J., Raizada, M.K., and Shenoy, V. (2015).
- ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy.
- Journal of Cardiovascular Pharmacology *66*, 540–550.
- Gilbert, J.A., Blaser, M.J., Caporaso, J.G., Jansson, J.K., Lynch, S. V, and Knight, R.
- (2018). Current understanding of the human microbiome. Nature Medicine 24, 392–
 400.
- Gillet, L.C., Navarro, P., Tate, S., Röst, H., Selevsek, N., Reiter, L., Bonner, R., and
- Aebersold, R. (2012). Targeted data extraction of the MS/MS spectra generated by
- data-independent acquisition: a new concept for consistent and accurate proteome
- analysis. Mol. Cell. Proteomics. 11, O111.016717.
- 832 Harding, H.P., Zhang, Y., Zeng, H., Novoa, I., Lu, P.D., Calfon, M., Sadri, N., Yun,
- 833 C., Popko, B., Paules, R., et al. (2003). An integrated stress response regulates amino
- acid metabolism and resistance to oxidative stress. Molecular Cell 11, 619–633.
- 835 Hashimoto, T., Perlot, T., Rehman, A., Trichereau, J., Ishiguro, H., Paolino, M., Sigl,
- 836 V., Hanada, T., Hanada, R., Lipinski, S., et al. (2012). ACE2 links amino acid
- malnutrition to microbial ecology and intestinal inflammation. Nature 487, 477–481.
- 838 Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu,
- X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in
- 840 Wuhan, China. Lancet (London, England) *395*, 497–506.


- 841 Jiang, Y., Lü, X., Man, C., Han, L., Shan, Y., Qu, X., Liu, Y., Yang, S., Xue, Y., and
- 842 Zhang, Y. (2012). Lactobacillus acidophilus induces cytokine and chemokine
- production via NF-κB and p38 mitogen-activated protein kinase signaling pathways in
- intestinal epithelial cells. Clinical and Vaccine Immunology : CVI 19, 603–608.
- 845 Jin, X., Lian, J.-S., Hu, J.-H., Gao, J., Zheng, L., Zhang, Y.-M., Hao, S.-R., Jia, H.-Y.,
- Cai, H., Zhang, X.-L., et al. (2020). Epidemiological, clinical and virological
- characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with
- 848 gastrointestinal symptoms. Gut.
- Ke, G., Meng, Q., Finley, T., Wang, T., Chen, W., Ma, W., Ye, Q., and Liu, T.-Y.
- 850 (2017). LightGBM: A Highly Efficient Gradient Boosting Decision Tree. Nips '17 9.
- Kessner, D., Chambers, M., Burke, R., Agus, D., and Mallick, P. (2008).
- 852 ProteoWizard: open source software for rapid proteomics tools development.
- Bioinformatics (Oxford, England) 24, 2534–2536.
- Kim, Y., Sundrud, M.S., Zhou, C., Edenius, M., Zocco, D., Powers, K., Zhang, M.,
- Mazitschek, R., Rao, A., Yeo, C.-Y., et al. (2020). Aminoacyl-tRNA synthetase
- 856 inhibition activates a pathway that branches from the canonical amino acid response
- in mammalian cells. Proceedings of the National Academy of Sciences of the UnitedStates of America.
- Lee, S.M.L.S.-I. (2017). A Unified Apporach to Interpreting Model Predictions.
 NIPS.
- 861 Lin, L., Jiang, X., Zhang, Z., Huang, S., Zhang, Z., Fang, Z., Gu, Z., Gao, L., Shi, H.,
- Mai, L., et al. (2020). Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut.
- Liu, B., Woo, J., Tang, N., Ng, K., Ip, R., and Yu, A. (2001). Assessment of total
- 865 energy expenditure in a Chinese population by a physical activity questionnaire:
- examination of validity. International Journal of Food Sciences and Nutrition 52,
 269–282.
- Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., and Manson, J.J.
- 869 (2020). COVID-19: consider cytokine storm syndromes and immunosuppression.
- 870 Lancet (London, England) 395, 1033–1034.
- 871 Monteleone, G., Sarzi-puttini, P.C., and Ardizzone, S. (2020). Preventing
- 872 COVID-19-induced pneumonia with anticytokine therapy. The Lancet Rheumatology
- 873 *9913*, 30092–30098.
- 874 Murray, P.J. (2016). Amino acid auxotrophy as a system of immunological control
- nodes. Nature Immunology 17, 132–139.
- National Health Commission (NHC) of the PRC, N.A. of T.C.M. of the P. (2020).
- 877 Diagnosis and Treatment Plan of Corona Virus Disease 2019 (Tentative Sixth
- Edition). Guidance for Corona Virus Disease 2019: Prevention, Control and
- 879 Diagnosis and Management. Beijing, China: People's Medical Publishing House,.
- Ng, S.C., and Tilg, H. (2020). COVID-19 and the gastrointestinal tract: more than meets the eye. Gut.
- Pedregosa, F., Weiss, R., and Brucher, M. (2011). Scikit-learn : Machine Learning in
- 883 Python. 12, 2825–2830.
- Pohjavuori, E., Viljanen, M., Korpela, R., Kuitunen, M., Tiittanen, M., Vaarala, O.,

- and Savilahti, E. (2004). Lactobacillus GG effect in increasing IFN-gamma
- production in infants with cow's milk allergy. The Journal of Allergy and Clinical
 Immunology *114*, 131–136.
- 888 Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Quan, S., Zhang, F., Sun, R., Qian,
- L., et al. (2020). Proteomic and Metabolomic Characterization of COVID-19 Patient
- 890 Sera. MedRxiv, https://doi.org/10.1101/2020.04.07.20054585.
- Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A.R., Mujagic,
- Z., Jonkers, D.M.A.E., Masclee, A.A.M., Fu, J., et al. (2020). Impact of commonly
- used drugs on the composition and metabolic function of the gut microbiota. NatureCommunications *11*, 362.
- 895 World Health Organization (2020). Coronavirus disease (COVID-19) Pandemic.
- 896 <u>https://www.who.int/emergencies/diseases/novel-coronavirus-2019</u>; Accessed Apr. 18,
 897 2020
- 898 Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., and Zhou, Q. (2020). Structural basis for
- the recognition of SARS-CoV-2 by full-length human ACE2. Science (New York,
 N.Y.) *367*, 1444–1448.
- 901 Yang, Y., Shen, C., Li, J., Yuan, J., Yang, M., Wang, F., Li, G., Li, Y., Xing, L., Peng,
- 902 L., et al. (2020). Exuberant elevation of IP-10, MCP-3 and IL-1ra during
- 903 SARS-CoV-2 infection is associated with disease severity and fatal outcome.
- 904 MedRxiv, https://doi.org/10.1101/2020.03.02.20029975.
- 905 Yoshida, K., Matsumoto, T., Tateda, K., Uchida, K., Tsujimoto, S., and Yamaguchi,
- 906 K. (2001). Induction of interleukin-10 and down-regulation of cytokine production by
- Klebsiella pneumoniae capsule in mice with pulmonary infection. Journal of Medical
 Microbiology *50*, 456–461.
- 209 Zhang, C.-X., and Ho, S.C. (2009). Validity and reproducibility of a food frequency
- 910 Questionnaire among Chinese women in Guangdong province. Asia Pacific Journal of 911 Clinical Nutrition *18*, 240–250.
- 912 Zhang, H., Kang, Z., Gong, H., Xu, D., Wang, J., Li, Z., Li, Z., Cui, X., Xiao, J., Zhan,
- 913 J., et al. (2020). Digestive system is a potential route of COVID-19: an analysis of
- 914 single- cell coexpression pattern of key proteins in viral entry process. 1–9.
- 915 Zhang, S., Zeng, X., Ren, M., Mao, X., and Qiao, S. (2017). Novel metabolic and
- 916 physiological functions of branched chain amino acids: a review. Journal of Animal
- 917 Science and Biotechnology 8, 10.
- 918 Zhang, Z.-Q., He, L.-P., Liu, Y.-H., Liu, J., Su, Y.-X., and Chen, Y.-M. (2014).
- 919 Association between dietary intake of flavonoid and bone mineral density in middle
- aged and elderly Chinese women and men. Osteoporosis International: A Journal
- 921 Established as Result of Cooperation between the European Foundation for
- 922 Osteoporosis and the National Osteoporosis Foundation of the USA 25, 2417–2425.
- 923 Zhang CX, H.S. (2009). Validity and reproducibility of a food frequency
- 924 Questionnaire among Chinese women in Guangdong province. Asia Pac J Clin Nutr
 925 18, 240–250.
- 926 Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu,
- 927 X., et al. (2020). Clinical course and risk factors for mortality of adult inpatients with
- 928 COVID-19 in Wuhan, China: a retrospective cohort study. Lancet *395*, 1054–1062.
- 929

33

Figure 1







35

Figure 3






Prospective subset




Based on 20 OTUs

 Based on demographic and clinical factors









37

Figure 5








Figure S2






Figure S3





B ≥ 58 years








Table S1. Characteristics of the data analysis set^a

Characteristics	dataset1	dataset2	dataset3	dataset4	dataset5
No. of participants	990	301	366	987	1729
Age (year)	58.79 (5.64)	66.21 (6.41)	66.09 (5.27)	64.71 (5.77)	58.54 (6.06)
Sex					
Women	668 (67.5%)	227 (75.4%)	241 (65.8%)	690 (69.9%)	1159 (67.0%)
Men	322 (32.5%)	74 (24.6%)	125 (34.2%)	297 (30.1%)	570 (33.0%)
BMI, kg/m ²	23.55 (3.23)	23.57 (3.04)	23.90 (3.65)	23.63 (3.26)	23.27 (3.08)
Marital status,%					
Married	911 (92.0%)	261 (87.0%)	342 (93.4%)	884 (89.6%)	1572 (90.9%)
Others	79 (8.0%)	39 (13.0%)	24 (6.6%)	103 (10.4%)	157 (9.1%)
Education,%					
Middle school or lower	294 (29.7%)	82 (27.3%)	88 (24.0%)	254 (25.7%)	469 (27.1%)
High school or professional	433 (43.7%)	116 (38.7%)	161 (44.0%)	434 (44.0%)	800 (46.3%)
college					
University	263 (26.6%)	102 (34.0%)	117 (32.0%)	299 (30.3%)	460 (26.6%)
Income (Yuan/month/person), %					
≤500	21 (2.1%)	3 (1.0%)	7 (1.9%)	11 (1.1%)	25 (1.4%)
501-1500	258 (26.1%)	70 (23.3%)	112 (30.6%)	235 (23.8%)	385 (22.3%)
1501-3000	565 (57.1%)	136 (45.2%)	177 (48.4%)	567 (57.4%)	1091 (63.1%)
>3000	146 (14.7%)	92 (30.6%)	70 (19.1%)	174 (17.6%)	228 (13.2%)
Current smoking status					
No	823 (83.1%)	268 (89.0%)	310 (84.7%)	858 (86.9%)	1458 (84.3%)
Yes	167 (16.9%)	33 (11.0%)	56 (15.3%)	129 (13.1%)	271 (15.7%)
Current alcohol drinking					
No	924 (93.3%)	289 (96.0%)	341 (93.2%)	914 (92.6%)	1604 (92.8%)
Yes	66 (6.7%)	12 (4.0%)	25 (6.8%)	73 (7.4%)	125 (7.2%)

^aValues are numbers (percentages) or mean (SD).

Table S2: List of the 20 proteomic biomarkers integrated in the proteomic risk score

Uniprot ID	Name	Annotation
Q9UK55	SERPINA10	Protein Z-dependent protease inhibitor; Inhibits activity of the coagulation protease
		factor Xa in the presence of PROZ, calcium and phospholipids. Also inhibits factor
		XIa in the absence of cofactors; Belongs to the serpin family
Q96PD5	PGLYRP2	N-acetylmuramoyl-L-alanine amidase; May play a scavenger role by digesting
		biologically active peptidoglycan (PGN) into biologically inactive fragments. Has no
		direct bacteriolytic activity; Belongs to the N-acetylmuramoyl-L-alanine amidase 2
		family
Q14520	HABP2	Hyaluronan-binding protein 2; Cleaves the alpha-chain at multiple sites and the beta-
		chain between 'Lys-53' and 'Lys-54' but not the gamma-chain of fibrinogen and
		therefore does not initiate the formation of the fibrin clot and does not cause the
		fibrinolysis directly. It does not cleave (activate) prothrombin and plasminogen but
		converts the inactive single chain urinary plasminogen activator (pro- urokinase) to
		the active two chain form. Activates coagulation factor VII. May function as a tumor
		suppressor negatively regulating cell proliferation and cell migration
Q06033	ITIH3	Inter-alpha-trypsin inhibitor heavy chain H3; May act as a carrier of hyaluronan in
		serum or as a binding protein between hyaluronan and other matrix protein, including
		those on cell surfaces in tissues to regulate the localization, synthesis and degradation
		of hyaluronan which are essential to cells undergoing biological processes
P51884	LUM	Lumican; Small leucine rich repeat proteoglycans; Belongs to the small leucine-rich
		proteoglycan (SLRP) family. SLRP class II subfamily
P18428	LBP	Lipopolysaccharide-binding protein; Plays a role in the innate immune response.
		Binds to the lipid A moiety of bacterial lipopolysaccharides (LPS), a glycolipid
		present in the outer membrane of all Gram-negative bacteria. Acts as an affinity
		enhancer for CD14, facilitating its association with LPS. Promotes the release of
		cytokines in response to bacterial lipopolysaccharide; BPI fold containing
P15169	CPN1	Carboxypeptidase N catalytic chain; Protects the body from potent vasoactive and
		inflammatory peptides containing C-terminal Arg or Lys (such as kinins or
		anaphylatoxins) which are released into the circulation; M14 carboxypeptidases
P13796	LCP1	Plastin-2; Actin-binding protein. Plays a role in the activation of T-cells in response
		to costimulation through TCR/CD3 and CD2 or CD28. Modulates the cell surface
		expression of IL2RA/CD25 and CD69; EF-hand domain containing
P13671	C6	Complement component C6; Constituent of the membrane attack complex (MAC)
		that plays a key role in the innate and adaptive immune response by forming pores in
		the plasma membrane of target cells; Complement system
P12259	F5	Coagulation factor V; Central regulator of hemostasis. It serves as a critical cofactor
		for the prothrombinase activity of factor Xa that results in the activation of
		prothrombin to thrombin
P0DJI9	SAA2	Serum amyloid A-2 protein; Major acute phase reactant. Apolipoprotein of the HDL
		complex; Belongs to the SAA family
P0DJI8	SAA1	Serum amyloid A-1 protein; Major acute phase protein; Belongs to the SAA family
1 010510	9771	Seram anytoid A-1 protoni, Major actic phase protoni, belongs to the SAA falling

P05452	CLEC3B	Tetranectin; Tetranectin binds to plasminogen and to isolated kringle 4. May be
		involved in the packaging of molecules destined for exocytosis; C-type lectin domair containing
P05155	SERPING1	Plasma protease C1 inhibitor; Activation of the C1 complex is under control of the
05155	SERIINOI	C1- inhibitor. It forms a proteolytically inactive stoichiometric complex with the C1
		or C1s proteases. May play a potentially crucial role in regulating important
		physiological pathways including complement activation, blood coagulation
		fibrinolysis and the generation of kinins. Very efficient inhibitor of FXIIa. Inhibits
000000		chymotrypsin and kallikrein; Serpin peptidase inhibitors
202768	ALB	Serum albumin; Serum albumin, the main protein of plasma, has a good binding
		capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs
		Its main function is the regulation of the colloidal osmotic pressure of blood. Major
		zinc transporter in plasma, typically binds about 80% of all plasma zinc; Belongs to
		the ALB/AFP/VDB family
P02750	LRG1	Leucine rich alpha-2-glycoprotein 1
P02748	C9	Complement component C9; Constituent of the membrane attack complex (MAC
		that plays a key role in the innate and adaptive immune response by forming pores in
		the plasma membrane of target cells. C9 is the pore- forming subunit of the MAC
		Belongs to the complement C6/C7/C8/C9 family
201011	GIG25	Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3
		Although its physiological function is unclear, it can inhibit neutrophil cathepsin C
		and mast cell chymase, both of which can convert angiotensin-1 to the active
		angiotensin-2; Serpin peptidase inhibitors
P00751	CFB	Complement factor B; Factor B which is part of the alternate pathway of the
		complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine
		protease, then combines with complement factor 3b to generate the C3 or C3
		convertase. It has also been implicated in proliferation and differentiation o
		preactivated B- lymphocytes, rapid spreading of peripheral blood monocytes
		stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the
		proliferation of preactivated B-lymphocytes; Belongs to the peptidase S1 family
P00738	HP	Haptoglobin; As a result of hemolysis, hemoglobin is found to accumulate in the
		kidney and is secreted in the urine. Haptoglobin captures, and combines with free
		plasma hemoglobin to allow hepatic recycling of heme iron and to prevent kidney
		damage. Haptoglobin also acts as an Antimicrobial; Antioxidant, has antibacteria
		activity and plays a role in modulating many aspects of the acute phase response
		Hemoglobin/haptoglobin complexes are rapidely cleared by the macrophage CD163
		scavenger receptor expressed on the surface of liver Kupfer cells through ar
		endocytic lysosomal degradation.

44

OTUs	Taxa annotation
OTU30210_Clostridiales	k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_; g_; s_
spp	
OTU1090_Unassigned 2	Unassigned
OTU174751_Clostridiu	k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_Clostridiaceae; g_Clostridium; s_
m <i>spp</i>	
OTU175355_Ruminococ	k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_Lachnospiraceae;
cus gnavus	g[Ruminococcus]; sgnavus
OTU1954_Unassigned 1	Unassigned
OTU198475_Ruminococ	k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_Ruminococcaceae; g_; s_
caceae spp 1	
OTU212681_Blautia spp	k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_Lachnospiraceae; g_Blautia; s_
OTU27582_Klebsiella	k_Bacteria; p_Proteobacteria; c_Gammaproteobacteria; o_Enterobacteriales;
spp	fEnterobacteriaceae; gKlebsiella; s
OTU30109_Streptococcu	k_Bacteria; p_Firmicutes; c_Bacilli; o_Lactobacillales; f_Streptococcaceae;
s spp 2	gStreptococcus; s
OTU358_Bacteroides	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Bacteroidaceae;
ovatus 2	g_Bacteroides; s_ovatus
OTU3653_Bacteroides	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Bacteroidaceae;
ovatus 1	g_Bacteroides; s_ovatus
OTU437_Streptococcus	k_Bacteria; p_Firmicutes; c_Bacilli; o_Lactobacillales; f_Streptococcaceae;
spp 1	g_Streptococcus; s_
OTU662_Streptococcus	k_Bacteria; p_Firmicutes; c_Bacilli; o_Lactobacillales; f_Streptococcaceae;
spp 3	gStreptococcus; s
OTU743_Unassigned 3	Unassigned
OTU808_Lactobacillus	k_Bacteria; p_Firmicutes; c_Bacilli; o_Lactobacillales; f_Lactobacillaceae; g_Lactobacillus;
spp	S
OTU87798_Bacteroides	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Bacteroidaceae;
spp 2	g_Bacteroides; s
OTU87996_Bacteroides	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Bacteroidaceae;
ovatus 3	g_Bacteroides; s_ovatus
OTU88234_Bacteroides	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Bacteroidaceae;
spp 3	g_Bacteroides; s
OTU91647_Ruminococc	k_Bacteria; p_Firmicutes; c_Clostridia; o_Clostridiales; f_Ruminococcaceae; g_; s_
aceae spp 2	
OTU92227_Bacteroides	k_Bacteria; p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Bacteroidaceae;
spp 1	g_Bacteroides; s_

Table S3: List and taxonomic classifications of the PRS-related core microbial OTUs